Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment

Histone deacetylase (HDAC) inhibitors have enormous therapeutic potential as effective epigenetic regulators, and now with the focus on the selective HDAC6 inhibitor in ongoing clinical trials, more advantages over other non-selective pan-HDAC inhibitors are foreseeable. As it is of paramount import...

Descripción completa

Detalles Bibliográficos
Autores principales: Pu, Jingjing, Liu, Ting, Sharma, Amit, Schmidt-Wolf, Ingo G. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657130/
https://www.ncbi.nlm.nih.gov/pubmed/37978516
http://dx.doi.org/10.1186/s12920-023-01724-3
Descripción
Sumario:Histone deacetylase (HDAC) inhibitors have enormous therapeutic potential as effective epigenetic regulators, and now with the focus on the selective HDAC6 inhibitor in ongoing clinical trials, more advantages over other non-selective pan-HDAC inhibitors are foreseeable. As it is of paramount importance to understand the complex regulatory web of mutual interactions involving epigenetic machinery and non-coding genome in regulating gene expression, herein, we investigated the intriguing interactions between HDAC6-induced lncRNA (LINC00152) and its possible sponge miRNA (hsa-miR-499a-5p) in multiple myeloma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12920-023-01724-3.

Ejemplares similares